Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD): an open-label pragmatic feasibility randomised controlled trial.
Subhani M, Enki DG, Knight H, Jones KA, Sprange K, Rennick-Egglestone S, Morling JR, Wragg A, Hutton C, Ryder SD. Subhani M, et al. Among authors: ryder sd. EClinicalMedicine. 2023 Jun 30;61:102069. doi: 10.1016/j.eclinm.2023.102069. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37448808 Free PMC article.
Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II).
Aspinall RJ, Hudson M, Ryder SD, Richardson P, Farrington E, Wright M, Przemioslo RT, Perez F, Kent M, Henrar R, Hickey J, Shawcross DL. Aspinall RJ, et al. Among authors: ryder sd. Frontline Gastroenterol. 2022 Nov 10;14(3):228-235. doi: 10.1136/flgastro-2022-102221. eCollection 2023. Frontline Gastroenterol. 2022. PMID: 37056320 Free PMC article.
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
Jacobson IM, Bourgeois S, Mathurin P, Thuluvath P, Ryder SD, Gerken G, Hernandez C, Vanstraelen K, Scherbakovsky S, Osinusi A, Tedesco D, Foster GR. Jacobson IM, et al. Among authors: ryder sd. J Viral Hepat. 2023 May;30(5):448-454. doi: 10.1111/jvh.13814. Epub 2023 Mar 2. J Viral Hepat. 2023. PMID: 36740893 Clinical Trial.
In severe alcohol-related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL-8 and micro-RNAs.
Tyson LD, Atkinson S, Hunter RW, Allison M, Austin A, Dear JW, Forrest E, Liu T, Lord E, Masson S, Nunes J, Richardson P, Ryder SD, Wright M, Thursz M, Vergis N. Tyson LD, et al. Among authors: ryder sd. Aliment Pharmacol Ther. 2023 Dec;58(11-12):1217-1229. doi: 10.1111/apt.17733. Epub 2023 Oct 2. Aliment Pharmacol Ther. 2023. PMID: 37781965 Free PMC article.
The Liverpool alcohol-related liver disease algorithm identifies twice as many emergency admissions compared to standard methods when applied to Hospital Episode Statistics for England.
Dhanda A, Bodger K, Hood S, Henn C, Allison M, Amasiatu C, Burton R, Cramp M, Forrest E, Khetani M, MacGilchrist A, Masson S, Parker R, Sheron N, Simpson K, Vergis N, White M; BASL ARLD SIG National Service Evaluation Group. Dhanda A, et al. Aliment Pharmacol Ther. 2023 Feb;57(4):368-377. doi: 10.1111/apt.17307. Epub 2022 Nov 17. Aliment Pharmacol Ther. 2023. PMID: 36397658 Free PMC article.
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus.
Sy A, McCabe L, Hudson E, Ansari AM, Pedergnana V, Lin SK, Santana S, Fiorino M, Ala A, Stone B, Smith M, Nelson M, Barclay ST, McPherson S, Ryder SD, Collier J, Barnes E, Walker AS, Pett SL, Cooke G; STOP-HCV-1 trial team. Sy A, et al. Among authors: ryder sd. PLoS One. 2023 Jan 23;18(1):e0280551. doi: 10.1371/journal.pone.0280551. eCollection 2023. PLoS One. 2023. PMID: 36689413 Free PMC article.
Use of non-selective B-blockers is safe in hospitalised decompensated cirrhosis patients and exerts a potential anti-inflammatory effect: Data from the ATTIRE trial.
Tittanegro T, China L, Forrest E, Kallis Y, Ryder SD, Wright G, Freemantle N, O'Brien A. Tittanegro T, et al. Among authors: ryder sd. EClinicalMedicine. 2022 Nov 14;55:101716. doi: 10.1016/j.eclinm.2022.101716. eCollection 2023 Jan. EClinicalMedicine. 2022. PMID: 36407574 Free PMC article.
Investigating potential confounding by indication when considering the association between proton pump inhibitor use, infection, hepatic encephalopathy and mortality in hospitalised decompensated cirrhosis: a post-hoc analysis of the ATTIRE trial.
China L, Tittanegro T, Crocombe D, Forrest E, Kallis Y, Ryder SD, Wright G, Freemantle N, O'Brien A. China L, et al. Among authors: ryder sd. EClinicalMedicine. 2023 Apr 4;58:101924. doi: 10.1016/j.eclinm.2023.101924. eCollection 2023 Apr. EClinicalMedicine. 2023. PMID: 37090442 Free PMC article.
147 results